Innovus Reports Successful Top Line Results From Vesele(R) in Erectile Dysfunction

​Innovus Pharmaceuticals Inc. (OTCMKTS:INNV) announced top line results from its Vesele(R) U.S. human survey use clinical trial in people with low erectile dysfunction.

Vesele(R) use resulted in the following:

• 49.5 percent increase in erection hardness
• 44.5 percent increase in erection maintenance
• 34.6 percent increase in desire for sexual activity
• 34.1 percent increase the ability to satisfy the partner
• 44 percent increase in overall satisfaction

About the VES-001 use survey trial:

• Method: Scores were assessed at initiation of trial, midpoint and conclusion. A five‐ point satisfaction scale was used. Satisfaction was summarized by combining scores from Mostly Satisfied, Satisfied, and Very Satisfied. Dissatisfaction was summarized using results from Dissatisfied and Very Dissatisfied.
• Subjects: 72 patients completed the trial in the United States.
• Age: Over 50 percent of participants who completed the trial were between the ages of 40‐59. Over 70% were age 40 and older. This was true at baseline as well
• Regimen: two capsules twice a day for a total of 16 weeks

As quoted in the press release:

Pursuant to these clinical trials, the data indicate that Vesele(R) was very well tolerated with no serious adverse events reported. The only minor events reported were dry mouth which resolved by drinking 62oz of water daily and sleep disturbance if taken late afternoon.

Vesele(R) is a proprietary oral formulation of arginine and citrulline with the natural absorption enhancer Bioperine(R). Vesele(R) was formulated to increase blood flow and nitric oxide production.

Dr. Bassam Damaj, president & CEO of the Innovus Pharma, commented:

We are thrilled about these results from the Vesele(R) trial which we believe confirms that activity of the product and increase its commercial potential. Erection hardness and maintenance is one of the main complaints of PDE5 drugs approved for erectile dysfunction and we see Vesele(R) as a great product to help with these complaints. Erectile dysfunction is a $5 billion dollar worldwide market that Innovus can tap into.

Click here to read the full ​Innovus Pharmaceuticals Inc. (OTCMKTS:INNV) press release.